相关实验视频
Updated: Jan 13, 2026

08:49
Murine Ileocolic Bowel Resection with Primary Anastomosis
Published on: October 29, 2014
17.2K
手术前的生物学因素与炎症性肠病手术后的术后并发症无关:国家手术质量改善计划炎症性肠病协作因果推断分析
Stefan D Holubar1, Tara Russell2, Nicholas Neel3
1Cleveland Clinic Foundation, Cleveland, Ohio.
Diseases of the colon and rectum
|January 6, 2026
概括
在炎症性肠道疾病手术前对生物制剂的术前暴露是安全的. 在手术后60天内使用生物治疗并没有增加患有炎症性肠病的患者的术后不良事件或并发症.
科学领域:
- 胃肠病学 胃肠病学
- 手术瘤学手术瘤学
- 免疫学 免疫学 免疫学
背景情况:
- 在接受手术的炎症性肠病 (IBD) 患者中,手术前生物暴露的安全性受到争论.
- 关于术后生物药物与IBD手术结果之间的关联现有的研究是有争议的.
研究的目的:
- 调查IBD手术后60天内生物暴露的安全性.
- 为了确定生物使用是否会增加IBD患者的术后不良事件.
主要方法:
- 一项多中心国家队列研究包括来自24个中心 (2020-2024) 的成人IBD患者.
- 该研究分析了30天内术后不良事件的发生率,重点关注传染病和整体并发症.
- 基于倾向分数的因果推理建模被用于评估手术后60天内生物暴露的影响.
主要成果:
- 在2926名患者中,48.8%接受了手术前的生物药物治疗.
- 生物组具有不同的手术前特征和手术内细节,包括更短的手术时间和更少的侵入性手术.
- 反向概率治疗权重显示,生物药物与术后感染增加 (RR 0.97),并发症 (RR 0.92) 或不良事件 (RR 0.92) 之间没有关联.
结论:
- 在IBD手术后60天内进行手术前的生物暴露与术后不良结果的增加无关.
- 这些发现表明,在IBD手术前使用生物药物是安全的,并且不会增加短期不良结果.
- 限制包括概括性,潜在的选择偏差,未测量的混因素和定义的60天生物暴露窗口.
相关概念视频
Inflammatory Bowel Disease V: Surgical Management
438
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
438
Inflammatory Bowel Disease IV: Pharmacological Management
471
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
471
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
478
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
478
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
425
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
425
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
177
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
177
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480

